{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Bronchogenic&page=38",
    "query": {
      "condition": "Carcinoma, Bronchogenic",
      "page": 38
    },
    "page_size": 10
  },
  "pagination": {
    "page": 38,
    "page_size": 10,
    "total_count": 3586,
    "total_pages": 359,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Bronchogenic&page=39&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Bronchogenic&page=37&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-17T06:36:05.768Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00005865",
      "title": "Vinorelbine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "vinorelbine tartrate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2000-04",
      "completion_date": "2007-06",
      "has_results": false,
      "last_update_posted_date": "2014-01-06",
      "last_synced_at": "2026-10-17T06:36:05.768Z",
      "location_count": 46,
      "location_summary": "Tucson, Arizona • Fayetteville, Arkansas • Hot Springs, Arkansas + 38 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Fairfield",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005865"
    },
    {
      "nct_id": "NCT02635672",
      "title": "Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "VIP152 (BAY 1251152)",
          "type": "DRUG"
        },
        {
          "name": "VIP152 (BAY 1251152) 30 mg",
          "type": "DRUG"
        },
        {
          "name": "Keytruda",
          "type": "DRUG"
        },
        {
          "name": "VIP152 (BAY 1251152) 15 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vincerx Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 110,
      "start_date": "2016-02-10",
      "completion_date": "2024-11-11",
      "has_results": false,
      "last_update_posted_date": "2024-11-15",
      "last_synced_at": "2026-10-17T06:36:05.768Z",
      "location_count": 13,
      "location_summary": "Springdale, Arkansas • Louisville, Kentucky • Silver Spring, Maryland + 10 more",
      "locations": [
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Silver Spring",
          "state": "Maryland"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02635672"
    },
    {
      "nct_id": "NCT00025571",
      "title": "Photodynamic Therapy With HPPH in Treating Patients With Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "HPPH",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2001-06",
      "completion_date": "2004-10",
      "has_results": false,
      "last_update_posted_date": "2011-03-07",
      "last_synced_at": "2026-10-17T06:36:05.768Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00025571"
    },
    {
      "nct_id": "NCT01237171",
      "title": "A Study of Cesium-131 Brachytherapy Following Sub-Lobar Resection for Early Stage Non Small Cell Lung Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "NSCLC",
        "Non Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Cesium-131 Brachytherapy Seed",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "IsoRay Medical, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 0,
      "start_date": "2010-11",
      "completion_date": "2010-11",
      "has_results": false,
      "last_update_posted_date": "2021-03-30",
      "last_synced_at": "2026-10-17T06:36:05.768Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01237171"
    },
    {
      "nct_id": "NCT07189871",
      "title": "177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Castration-Resistant Prostate Cancer (CRPC)",
        "Colorectal Cancer",
        "NSCLC (Non-small Cell Lung Cancer)",
        "Ovarian Cancer",
        "Cervical Cancer",
        "Endometrial Cancer",
        "TNBC, Triple Negative Breast Cancer",
        "Small Cell Lung Cancer (SCLC )",
        "Head &Amp; Neck Squamous Cell Carcinoma (HNSCC)",
        "Esophageal Squamous Cell Carcinoma (ESCC)",
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "177Lu-BetaBart",
          "type": "DRUG"
        },
        {
          "name": "BetaBart + unlabeled BetaBart",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Radiopharm Theranostics, Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 61,
      "start_date": "2026-02-23",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-10-01",
      "last_synced_at": "2026-10-17T06:36:05.768Z",
      "location_count": 5,
      "location_summary": "Dothan, Alabama • Grand Rapids, Michigan • Omaha, Nebraska + 1 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07189871"
    },
    {
      "nct_id": "NCT06764771",
      "title": "A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Malignant Tumors"
      ],
      "interventions": [
        {
          "name": "BMS-986488",
          "type": "DRUG"
        },
        {
          "name": "Adagrasib",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 437,
      "start_date": "2025-03-25",
      "completion_date": "2027-10-15",
      "has_results": false,
      "last_update_posted_date": "2026-07-29",
      "last_synced_at": "2026-10-17T06:36:05.768Z",
      "location_count": 4,
      "location_summary": "Hackensack, New Jersey • Allentown, Pennsylvania • Germantown, Tennessee + 1 more",
      "locations": [
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Allentown",
          "state": "Pennsylvania"
        },
        {
          "city": "Germantown",
          "state": "Tennessee"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06764771"
    },
    {
      "nct_id": "NCT03829332",
      "title": "Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Lenvatinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo for lenvatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 623,
      "start_date": "2019-03-13",
      "completion_date": "2024-04-24",
      "has_results": true,
      "last_update_posted_date": "2026-02-19",
      "last_synced_at": "2026-10-17T06:36:05.768Z",
      "location_count": 18,
      "location_summary": "Anchorage, Alaska • Chandler, Arizona • Bakersfield, California + 15 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03829332"
    },
    {
      "nct_id": "NCT03041311",
      "title": "Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Trilaciclib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "G1 Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 107,
      "start_date": "2017-06-29",
      "completion_date": "2020-10-29",
      "has_results": true,
      "last_update_posted_date": "2025-09-25",
      "last_synced_at": "2026-10-17T06:36:05.768Z",
      "location_count": 23,
      "location_summary": "Beverly Hills, California • Fullerton, California • Loma Linda, California + 19 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03041311"
    },
    {
      "nct_id": "NCT06244771",
      "title": "A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumors With KRAS G12C Mutations",
        "Solid Tumor, Adult",
        "Unresectable Solid Tumor",
        "Metastatic Solid Tumor",
        "Non Small Cell Lung Cancer",
        "Colorectal Cancer",
        "KRAS G12C",
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "FMC-376",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Frontier Medicines Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 403,
      "start_date": "2024-02-12",
      "completion_date": "2028-04",
      "has_results": false,
      "last_update_posted_date": "2026-03-18",
      "last_synced_at": "2026-10-17T06:36:05.768Z",
      "location_count": 15,
      "location_summary": "La Jolla, California • Orange, California • San Francisco, California + 11 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Lake Mary",
          "state": "Florida"
        },
        {
          "city": "Dyer",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06244771"
    },
    {
      "nct_id": "NCT02669914",
      "title": "MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "Nonsmall Cell Lung Cancer",
        "Breast Cancer",
        "Cancer of Breast",
        "Cancer of the Breast",
        "Gastroesophageal Cancer",
        "Pancreatic Cancer",
        "Cancer of the Pancreas",
        "Colorectal Cancer",
        "Colorectal Carcinoma",
        "Renal Cancer",
        "Kidney Cancer",
        "Cancer of the Kidney",
        "Cancer of Kidney",
        "Ovarian Cancer",
        "Ovary Cancer",
        "Cancer of the Ovary",
        "Cancer of Ovary"
      ],
      "interventions": [
        {
          "name": "MEDI4736",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2016-09-12",
      "completion_date": "2018-01-11",
      "has_results": true,
      "last_update_posted_date": "2018-11-06",
      "last_synced_at": "2026-10-17T06:36:05.768Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02669914"
    }
  ]
}